Trial Profile
An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs TLC 388 (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Taiwan Liposome Company
- 23 Feb 2018 Status changed to discontinued.
- 22 Oct 2014 New trial record